589 related articles for article (PubMed ID: 34518290)
1. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
Greten TF; Abou-Alfa GK; Cheng AL; Duffy AG; El-Khoueiry AB; Finn RS; Galle PR; Goyal L; He AR; Kaseb AO; Kelley RK; Lencioni R; Lujambio A; Mabry Hrones D; Pinato DJ; Sangro B; Troisi RI; Wilson Woods A; Yau T; Zhu AX; Melero I
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518290
[TBL] [Abstract][Full Text] [Related]
2. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
Emens LA; Adams S; Cimino-Mathews A; Disis ML; Gatti-Mays ME; Ho AY; Kalinsky K; McArthur HL; Mittendorf EA; Nanda R; Page DB; Rugo HS; Rubin KM; Soliman H; Spears PA; Tolaney SM; Litton JK
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389617
[TBL] [Abstract][Full Text] [Related]
3. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.
Govindan R; Aggarwal C; Antonia SJ; Davies M; Dubinett SM; Ferris A; Forde PM; Garon EB; Goldberg SB; Hassan R; Hellmann MD; Hirsch FR; Johnson ML; Malik S; Morgensztern D; Neal JW; Patel JD; Rimm DL; Sagorsky S; Schwartz LH; Sepesi B; Herbst RS
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640927
[TBL] [Abstract][Full Text] [Related]
4. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.
Silk AW; Barker CA; Bhatia S; Bollin KB; Chandra S; Eroglu Z; Gastman BR; Kendra KL; Kluger H; Lipson EJ; Madden K; Miller DM; Nghiem P; Pavlick AC; Puzanov I; Rabinowits G; Ruiz ES; Sondak VK; Tavss EA; Tetzlaff MT; Brownell I
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902131
[TBL] [Abstract][Full Text] [Related]
5. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.
Galsky MD; Balar AV; Black PC; Campbell MT; Dykstra GS; Grivas P; Gupta S; Hoimes CJ; Lopez LP; Meeks JJ; Plimack ER; Rosenberg JE; Shore N; Steinberg GD; Kamat AM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266883
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
Liu X; Qin S
Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
[TBL] [Abstract][Full Text] [Related]
7. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
Brahmer JR; Abu-Sbeih H; Ascierto PA; Brufsky J; Cappelli LC; Cortazar FB; Gerber DE; Hamad L; Hansen E; Johnson DB; Lacouture ME; Masters GA; Naidoo J; Nanni M; Perales MA; Puzanov I; Santomasso BD; Shanbhag SP; Sharma R; Skondra D; Sosman JA; Turner M; Ernstoff MS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172516
[TBL] [Abstract][Full Text] [Related]
8. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.
Disis ML; Adams SF; Bajpai J; Butler MO; Curiel T; Dodt SA; Doherty L; Emens LA; Friedman CF; Gatti-Mays M; Geller MA; Jazaeri A; John VS; Kurnit KC; Liao JB; Mahdi H; Mills A; Zsiros E; Odunsi K
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295818
[TBL] [Abstract][Full Text] [Related]
9. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
10. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
[TBL] [Abstract][Full Text] [Related]
11. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
[TBL] [Abstract][Full Text] [Related]
12. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
Wong KM; King GG; Harris WP
Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
[TBL] [Abstract][Full Text] [Related]
13. TKIs in combination with immunotherapy for hepatocellular carcinoma.
Stefanini B; Ielasi L; Chen R; Abbati C; Tonnini M; Tovoli F; Granito A
Expert Rev Anticancer Ther; 2023 Mar; 23(3):279-291. PubMed ID: 36794716
[TBL] [Abstract][Full Text] [Related]
14. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapy of liver cancer.
Demir T; Lee SS; Kaseb AO
Adv Cancer Res; 2021; 149():257-294. PubMed ID: 33579425
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
[TBL] [Abstract][Full Text] [Related]
17. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma.
Neelapu SS; Adkins S; Ansell SM; Brody J; Cairo MS; Friedberg JW; Kline JP; Levy R; Porter DL; van Besien K; Werner M; Bishop MR
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361336
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular Carcinoma Immunotherapy.
Sperandio RC; Pestana RC; Miyamura BV; Kaseb AO
Annu Rev Med; 2022 Jan; 73():267-278. PubMed ID: 34606324
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in Hepatocellular Carcinoma.
Fulgenzi CAM; Talbot T; Murray SM; Silletta M; Vincenzi B; Cortellini A; Pinato DJ
Curr Treat Options Oncol; 2021 Aug; 22(10):87. PubMed ID: 34424422
[TBL] [Abstract][Full Text] [Related]
20. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
